Gemphire Therapeutics Inc. (GEMP)
(Delayed Data from NSDQ)
$1.27 USD
+0.06 (4.96%)
Updated May 3, 2019 03:58 PM ET
After-Market: $1.23 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
NeuroBo Pharmaceuticals, Inc. [GEMP]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage following its merger with a neurodegenerative disease company that falls outside our coverage universe
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for GEMP
Provider: ValuEngine, Inc
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - AASLD Nonsense - Sense and the War of FXR Agonists
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The Liver Meeting Abstracts Part 1: Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Love NASH, Mark Your Calendar for October 17
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
Gemcabene Enters the NASH Arena in Fall With Phase 2 Results
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
Puts Itself Back into the CV Play with Impressive INDIGO Data
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
Healthcare - NASH Weekly: Our Clinicaltrials.gov tracker - Who Entered the NASH Arena?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
1Q18: Facing Major Inflection Point with INDIGO Data Around the Corner
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Unclassified
We are dropping coverage due to a reallocation of resources
Provider: H.C. Wainwright & Co., Inc.